Rathbones Group PLC Trims Stock Holdings in Guardant Health, Inc. $GH

Rathbones Group PLC decreased its stake in Guardant Health, Inc. (NASDAQ:GH) by 2.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 200,088 shares of the company’s stock after selling 5,877 shares during the quarter. Rathbones Group PLC’s holdings in Guardant Health were worth $12,501,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. TD Waterhouse Canada Inc. grew its stake in shares of Guardant Health by 3.2% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock valued at $306,000 after acquiring an additional 151 shares during the period. PNC Financial Services Group Inc. increased its holdings in Guardant Health by 8.3% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,016 shares of the company’s stock worth $251,000 after acquiring an additional 307 shares in the last quarter. Main Management ETF Advisors LLC raised its stake in Guardant Health by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 21,257 shares of the company’s stock worth $1,106,000 after acquiring an additional 348 shares during the period. CWM LLC lifted its holdings in Guardant Health by 21.6% during the third quarter. CWM LLC now owns 2,020 shares of the company’s stock valued at $126,000 after purchasing an additional 359 shares in the last quarter. Finally, Trivium Point Advisory LLC lifted its holdings in Guardant Health by 8.1% during the third quarter. Trivium Point Advisory LLC now owns 5,167 shares of the company’s stock valued at $323,000 after purchasing an additional 385 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Price Performance

Guardant Health stock opened at $91.20 on Monday. Guardant Health, Inc. has a 1 year low of $34.88 and a 1 year high of $120.74. The firm’s 50 day moving average price is $105.29 and its 200-day moving average price is $89.12. The stock has a market cap of $11.96 billion, a P/E ratio of -27.55 and a beta of 1.67.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. The business’s revenue was up 39.4% compared to the same quarter last year. During the same period last year, the company posted ($0.62) EPS. As a group, equities analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Buying and Selling at Guardant Health

In other news, CEO Helmy Eltoukhy sold 90,565 shares of Guardant Health stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $103.82, for a total value of $9,402,458.30. Following the sale, the chief executive officer directly owned 2,047,143 shares of the company’s stock, valued at approximately $212,534,386.26. The trade was a 4.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CTO Darya Chudova sold 5,451 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $104.04, for a total value of $567,122.04. Following the completion of the sale, the chief technology officer owned 7,012 shares in the company, valued at $729,528.48. This represents a 43.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 114,734 shares of company stock valued at $12,083,490 in the last 90 days. Insiders own 6.10% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on GH. Barclays reissued an “overweight” rating and issued a $130.00 price objective on shares of Guardant Health in a research note on Friday, February 20th. TD Cowen lifted their target price on shares of Guardant Health from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, January 22nd. Mizuho set a $135.00 price target on Guardant Health in a research note on Friday, January 9th. Finally, Piper Sandler raised their price target on Guardant Health from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Tuesday, February 24th. Twenty-one equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $122.57.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.